INTRODUCTION
============

The spine is the most common site of bony metastatic disease. At least 40% of patients with advanced cancer will have spinal involvement during the course of their disease and approximately 5-10% of these patients will develop some type of epidural cord compression. More than 90% of metastatic lesions involving the spine are extradural; intradural and intramedullary lesions represent \<5% and \<1% of lesions, respectively [@b1-cln_71p101][@b2-cln_71p101][@b3-cln_71p101].

Up to 50% of metastatic lesions originate from breast, lung or prostate cancers. With improved systemic treatment and augmented survival times, a greater number of patients with other tumor histologies will develop secondary lesions [@b1-cln_71p101].

Early diagnosis of spinal metastatic disease is critical because functional outcomes depend on neurologic condition at the time of presentation. Tumor-related pain typically appears early in the morning or at night, generally improves with physical activity and frequently precedes the development of other neurological symptoms by weeks or months [@b4-cln_71p101],[@b5-cln_71p101].

Uncontrolled spinal tumors typically produce pain and diminish ambulatory ability and performance status. Treatment is primarily palliative and is achieved by gaining local control of the disease. In selected cases, chemotherapy or surgery may pose as alternatives. The proper management of patients with spinal metastasis requires multidisciplinary treatment managed by orthopedic surgeons, neurosurgeons, radiation oncologists, medical oncologists, pain medicine specialists, radiologists and palliative care professionals.

Although palliative radiotherapy plays a prominent role in treating patients with metastatic spine disease, there is increasing literature that supports the use of stereotactic body radiotherapy (SBRT) or spine radiosurgery (SR)-based ablative treatment [@b6-cln_71p101][@b7-cln_71p101][@b8-cln_71p101].

SR is a recently developed radiation therapy technique that delivers high-dose radiation to a tumor while minimizing the radiation delivered to healthy, neighboring tissues. A treatment target is defined by high-resolution imaging, which is also used for treatment planning and dose calculation. Precise delineation of the spinal cord requires registration if computer tomography (CT) images to the T2-weighted magnetic resonance imaging (MRI) series, or a CT myelogram. Treatment is delivered using a combination of externally placed strict immobilization devices and image-guided (IG) intensity-modulated radiation therapy (IMRT) [@b9-cln_71p101][@b10-cln_71p101]. The treatment course is reduced to only a few sessions (generally up to 5), with total doses ranging from 12 to 30 Gy delivered in 1 to 5 fractions.

SR aims to improve existing rates of clinical response and tumor control, reduce re-treatment rates for metastatic lesions by increasing the biologic equivalent dose[1](#fn1){ref-type="fn"}, minimize radiation doses to healthy organs and allow safer reirradiation in previously treated sites [@b11-cln_71p101]. SR spares the spinal cord better than conventional radiotherapy and fractionated IMRT, even when very high doses are prescribed to an area only a few millimeters in size. Immobilization devices and image-guidance (IGRT) tools, such as kilovoltage cone-beam imaging [@b12-cln_71p101], have reduced treatment errors associated with traditional radiotherapy and enabled safe and accurate delivery of the highly conformal dose distributions produced by IMRT techniques [@b13-cln_71p101].

The aim of this article was to review published data on and ongoing trials of SR for metastatic tumors of the spine.

Review Methodology
------------------

A literature search was conducted using the MEDLINE database \[via PubMed\] and the Clinicaltrials.gov database for all article types available through September 2014. No other filter was activated and we assessed all of the published data that were available in English. Controlled vocabulary was leveraged as well as text words to develop the search strategy detailed below.

Our search terms and strategy used the following MEDLINE MeSH terms: ((Spinal Neoplasms \[MeSH\] OR Neoplasm, Spinal OR Neoplasms, Spinal OR Spinal Neoplasm OR Spine \[MeSH\] Vertebral Column OR Column, Vertebral OR Columns, Vertebral OR Vertebral Columns OR Spinal Column OR Column, Spinal OR Columns, Spinal OR Spinal Columns OR Vertebra OR Vertebrae) AND (Radiosurgery \[MeSH\] OR Radiosurgeries OR Radiosurgery, Stereotactic OR Radiosurgeries, Stereotactic OR Stereotactic Radiosurgeries OR Stereotactic Radiosurgery OR Gamma Knife Radiosurgery OR Gamma Knife Radiosurgeries OR Radiosurgeries, Gamma Knife OR Radiosurgery, Gamma Knife OR Stereotactic Body Radiotherapy OR Body Radiotherapies, Stereotactic OR Body Radiotherapy, Stereotactic OR Radiotherapies, Stereotactic Body OR Radiotherapy, Stereotactic Body OR Stereotactic Body Radiotherapies OR CyberKnife Radiosurgery OR CyberKnife Radiosurgeries OR Radiosurgeries, CyberKnife OR Radiosurgery, CyberKnife OR Radiosurgery, Linear Accelerator OR Linear Accelerator Radiosurgeries OR Radiosurgeries, Linear Accelerator OR Linear Accelerator Radiosurgery OR Radiosurgery, Linac OR Radiosurgeries, Linac OR LINAC Radiosurgery OR Radiosurgeries, LINAC)). For the Clinicaltrials.gov database, we used the following search terms: Spinal Neoplasms OR Spine AND Radiosurgery OR Radiation Therapy.

Two authors independently screened all identified studies by title and abstract. Studies with the following inclusion criteria were collected: primary focus on clinical outcome, evaluation of feasibility, assessment of toxicity and presentation of technical aspects. Additional treatment with chemotherapy, targeted therapy, endocrine therapy and surgery were permitted if radiotherapy was the primary intervention under investigation. All references in each included study were manually searched for important missed publications. Re-reporting and clinical trials were manually removed, and only the most recent publications were evaluated [@b14-cln_71p101][@b15-cln_71p101][@b16-cln_71p101].

Studies that did not focus on SR were removed. Articles published in languages other than English were excluded. We also excluded articles with a main focus of epidemiology, research design, diagnosis, basic science or clinical guidelines. Editorial commentaries were removed. Finally, we removed studies with fewer than 20 patients, heterogeneous treatment design (multiple levels of SR dose or SR not the main objective of analysis) and less than 6 months of follow-up. A third evaluator resolved any disagreements.

Review Results
--------------

We identified 663 studies \[MEDLINE n=285; Clinicaltrials.gov n=378\]). After assessing and removing duplicated records (n=10), 653 studies were screened; of these, only 155 met the eligibility criteria for full-text assessment. After manually screening the full-text articles of the remaining studies (n=155 \[MEDLINE n=132; Clinicaltrials.gov n=23) for our inclusion criteria, we identified 60 unique articles for qualitative analysis ([Figure 1](#f1-cln_71p101){ref-type="fig"}).

Data Extraction
---------------

One investigator (F.Y.M.) independently extracted data from all 60 studies. The following data were collected: study design, year of publication, non-radiotherapy interventions (e.g., hormone therapy, chemotherapy, targeted agents or procedures), type of radiotherapy treatment course (IMRT, IGRT, proton therapy, and brachytherapy), and primary assessed outcome \[overall survival (OS), local control, pain control, quality of life measures and toxicity\].

Technical Aspects of Spinal Radiosurgery
----------------------------------------

### Dose Delivery Technique: Intensity-Modulated Radiotherapy

The use of IMRT is required to deliver high-dose radiation to vertebra while simultaneously sparing the spinal cord and other adjacent critical organs (e.g., the esophagus or brachial plexus). The development of IMRT was a major improvement over 3D conformal radiotherapy (3DCRT) [@b17-cln_71p101]. IMRT is capable of modulating a target-shaped field of uniform radiation intensity into hundreds of pixel-like "beamlets", each with its own intensity. This advancement allows the delivery of increased radiation intensity to areas within the beam that are contained within the target volume only and reduces the radiation delivered to healthy organs via so-called intensity modulation. As a result, it is possible to create complex dose distributions characterized by steep dose gradients (i.e., significant dose differences over a short distance) to create a target (e.g., vertebra) with a concave shape to avoid hitting organs at risk (e.g., the spinal cord).

IMRT fields are often created through inverse planning optimization algorithms, where doses are prescribed to delineated volumes and potential plan alternatives are generated with guidance from a treatment planner (e.g., a dosimetrist or medical physicist) until a reasonable solution is found. Delivery via these intensity-modulated beams is achieved through the use of physical compensators (which are outdated technology) or, preferably, multi-leaf collimators (MLCs). An MLC serves as an add-on to a conventional rectangular linear accelerator\'s collimator. MLCs consist of sets of opposed leaf pairs (typically approximately 60 to 80 pairs of tungsten metal bars) that automatically longitudinally displace in and out of a beam\'s rectangular aperture to produce irregular custom shapes. Via the continuous or stepwise movement of the leaves during radiation emission, it is possible to modulate the intensity across a beam. This modulation of beam intensity improves the therapeutic index by allowing for increased target dose and reducing damage to normal tissues.

With the use of IMRT, a sharp dose gradient of approximately 10% per millimeter can be achieved near the spinal cord [@b18-cln_71p101]. For example, in a photon-based IMRT plan, where the spinal cord is 3 mm from the edge of the target volume, 18 Gy can be delivered to more than 90% of the target volume, while the maximum dose to the spinal cord surface would be less than 14 Gy ([Figure 2](#f2-cln_71p101){ref-type="fig"}).

The rationale for using proton and other particle beams is the ability to achieve excellent dose distribution at a tumor target with virtually no exit dose delivered beyond the target volume. The Bragg peak phenomenon associated with particle beam radiation results in an extremely steep dose fall-off over a course of a few millimeters ([Figure 3](#f3-cln_71p101){ref-type="fig"}). The advantage of this characteristic lies primarily in the lack of exit dose beyond the Bragg peak. However, there is currently no routine indication to use proton radiation for SR.

### Patient Setup: Immobilization and Image Guidance

The general treatment parameters for SR are currently based on the use of IMRT and, more recently, volumetric arc therapy (VMAT, which is dosimetrically equivalent but more efficient and faster than IMRT). In addition, SR requires the use of image guidance and setup verification. The overall precision of different components (e.g., mechanical aspects, image guidance and beam targeting) should allow treatment accuracy within 1 mm [@b19-cln_71p101]. The primary role of IGRT is to guide patient re-positioning based on a target itself (in this case, the vertebral body being treated). Secondly, depending on the IGRT technique, patient position can be monitored during treatment to assure that the target remains static through frequent intra-fraction imaging. IGRT also requires that a patient remain immobilized in the correct position throughout dose delivery; devices exist specifically for this purpose.

For SR, a patient is immobilized in a stereotactic body frame or immobilization cradle. Such devices are noninvasive and thus do not guarantee that a patient will remain perfectly positioned. Nonetheless, based on pre- and post-treatment imaging findings, an approximate 95% rate of immobilization accuracy has been reported for the noninvasive devices that are currently in use [@b20-cln_71p101]. Immobilization has emerged as an issue of great importance because planning technology is ineffective unless a patient is accurately positioned.

Accurate positioning is possible through patient cooperation. After proper positioning is achieved, image acquisition, ideally using onboard cone-beam imaging just before RT treatment, can be initiated. Pretreatment images are registered and compared with target images acquired during simulation to identify and correct setup errors. Typically, these variations are minimal and account for displacements of less than 3 millimeters from the ideal position. These displacements are accounted for by repositioning the patient to match the target before treatment begins. After corrections are made in each direction, spine positioning can be considered truly reliable for a treatment session, with less than 1 mm of error [@b21-cln_71p101].

### Clinical Assessment and Patient Selection

Due to the improved OS gained by improving local and systemic therapies and the capacity of SR to improve local tumor control, SR has great potential for increased utilization. Spine metastatic disease is often observed in radiation oncology clinics and studies of SR have indicated that the technique results in excellent local control rates [@b8-cln_71p101],[@b22-cln_71p101],[@b23-cln_71p101]. The indications for SR are still expanding; they currently include pain related to an involved vertebral body, radiographic tumor progression, lesions associated with progressive neurologic deficits, adjuvant therapy after surgical intervention for radioresistant metastasis and the need for reirradiation [@b8-cln_71p101].

Memorial Sloan Kettering Cancer Center (MSKCC) utilizes a multidisciplinary spine team to identify and treat patients who would most benefit from SR. The MSKCC Spine Clinic developed and now implements the algorithm NOMS for metastatic spine disease. This algorithm incorporates assessments of (N)eurologic condition, (O)ncologic status, (M)echanical instability and (S)ystemic disease [@b24-cln_71p101]. The goal of this decision framework is to provide a rapid, highly reliable assessment (e.g., low-grade extradural spinal cord compression (ESCC) *versus* high-grade disease or mechanical *versus* biologic pain) for the treatment of spinal metastases. Such treatment integrates radiation therapy, interventional neuroradiology and surgical approaches ([Table 1](#t1-cln_71p101){ref-type="table"}) [@b24-cln_71p101],[@b25-cln_71p101].

### Local Disease Control

Local control is defined as the absence of recurrent cord compression within an irradiated field or the absence of progression at a treatment site. The local control achieved with SR has been assessed in many series. Several of these series are highlighted below.

The Radiation Therapy Oncology Group (RTOG) published a phase II study evaluating the use of SR for localized spinal metastases (RTOG 0631). In this multicenter phase II study, patients with 1-3 lesions and a numerical rating pain scale score of ≥5 were treated. A total of 44 patients received 16-18 Gy of single-fraction SR. Grade 1/2 and grade 3 SBRT-related adverse events were observed in seven and zero patients, respectively. The investigators concluded that SR is safe and feasible in the multi-institutional setting [@b10-cln_71p101]. Several departments have also published their experiences, which are summarized in [Table 2](#t2-cln_71p101){ref-type="table"} [@b22-cln_71p101],[@b32-cln_71p101],[@b45-cln_71p101],.

For metastatic spinal tumors, SR has been postoperatively utilized in several series and in cases of progression following conventional fractionated palliative radiation treatment. Even in these challenging settings, SR achieves local control in approximately 85-94% of cases [@b22-cln_71p101],[@b23-cln_71p101],[@b26-cln_71p101],[@b18-cln_71p101],[@b27-cln_71p101]. When used as a primary treatment, long-term radiographic tumor control has been demonstrated in 90% of cases [@b22-cln_71p101],.

^In\ an\ assessment\ of\ 103\ consecutive\ spinal\ metastases\ in\ 93\ patients\ without\ high-grade\ ESCC\ who\ were\ treated\ with\ SBRT\ (median\ dose,\ 24\ Gy\ delivered\ in\ a\ single\ fraction;\ range,\ 18-24\ Gy),\ MSKCC\ reported\ an\ overall\ local\ control\ rate\ of\ 90%\ at\ a\ median\ follow-up\ of\ 15\ months.\ There\ were\ no\ deaths\ attributed\ to\ local\ failure.\ No\ patient\ experienced\ myelopathy\ or\ radiculopathy,\ even\ when\ the\ maximum\ spinal\ dose\ was\ raised\ to\ 14\ Gy\ from\ 12\ Gy^[@b23-cln_71p101].

In another phase I/II trial, 149 patients (166 metastatic spine lesions) were treated with SR. None of the patients showed evidence of mechanical instability or cord compression and 50% of them exhibited radioresistant tumor histology. Each of the patients received a total dose of 27-30 Gy, typically delivered in three fractions. More than half of the patients had been treated with one prior course of conventional radiation therapy (30 Gy delivered in ten fractions). The local tumor progression-free survival reported after SR was 81% at 1 year and 72% at 2 years. Adverse events were minimal and SR was associated with robust pain reduction (26% of the patients were pain-free before SR and 54% were pain-free 6 months after SR). SR also reduced pain medication use and was associated with improved quality of life [@b31-cln_71p101].

In another report, 88 patients with 120 spinal metastases from pathologically proven high-grade sarcoma were treated with hypofractionated \[3-6 fractions; median dose, 28.5 Gy; n=52 (43.3%)\] or single-fraction SR \[median dose, 24 Gy; n=68 (56.7%)\]. At a median follow-up of 12.3 months, the 12-month local control rate was 87.9%, and the OS was 60%. Single-fraction SR showed better local control than hypofractionation (*p*=0.007). The rate of adverse effects was low, and no grade \>3 toxicity was reported [@b32-cln_71p101].

### Pain Control

Despite the use of heterogeneous methods for pain evaluation (e.g., verbal analysis scale and subjective measurements of pain relief, among others), most series report very high pain control rates (up to 96%) at 12 months [@b8-cln_71p101]. Pain control rates were still high even in cases of radioresistant tumors, such as melanoma, sarcoma, renal cell tumors, non-small cell lung cancer, gastrointestinal tumors and others (96% and 85% rates of pain control were achieved for melanoma and renal cell carcinoma, respectively) [@b8-cln_71p101],[@b30-cln_71p101],[@b33-cln_71p101]. SR has also been reported to provide better pain control more rapidly than conventional radiotherapy, with pain relief sometimes observed within 24 hours of treatment [@b34-cln_71p101].

It is thought that conventional radiation doses may be sub-therapeutic for radioresistant tumors. A systematic review of randomized controlled trials (RCTs) reported that conventional radiotherapy can successfully palliate bone pain in 50 to 80% of patients, but complete pain relief is only achieved in up to 30% of patients [@b35-cln_71p101][@b36-cln_71p101]. Thus, SR is feasible for the treatment of spinal metastases and promotes high rates of local control and pain relief with low rates of toxicity.

### Postoperative Irradiation

It has been suggested that patients with metastatic spinal cord compression (MSCC) will benefit more from high-dose and/or SR radiotherapy than they would from low-dose fractioned radiotherapy. Surgery is fundamental the management of patients with symptomatic MSCC or high-grade spine compression. Patchell et al. reported in a RCT that surgical decompression is significantly beneficial. A larger number of patients who underwent surgery plus postoperative RT regained the ability to walk compared to those who received only RT. Ambulatory status was also maintained for longer in the surgery plus RT arm [@b37-cln_71p101].

However, the exact criteria for surgery in cases of MSCC remain controversial. The following factors are usually necessary for improved outcomes: favorable PS and expected OS, a relatively radioresistant tumor type and MSCC accompanied with mechanical instability [@b24-cln_71p101],[@b25-cln_71p101],[@b38-cln_71p101],[@b39-cln_71p101]. Epidural disease is an important limiting factor with respect to SR efficacy. Al-Omair et al. reported that epidural disease progression is the most common cause of treatment failure after SR and a significant predictor of poor local control [@b40-cln_71p101].

To more safely administer an ablative radiation dose, it may be possible to perform separation surgery to create a space of 2--3 mm between a metastatic lesion and the spinal cord. This allows a full dose to be administered to the entire tumor volume while minimizing the radiation dose delivered to the spinal cord. The surgical procedure is performed using epidural decompression and spinal stabilization without gross total or en bloc tumor resection [@b41-cln_71p101],[@b42-cln_71p101].

Recently, MSKCC has published their experiences with 186 patients treated from 2002 to 2011 who were managed with separation surgery followed by SR (hypofractionated or single fraction) [@b43-cln_71p101],[@b44-cln_71p101]. In this cohort, 136 patients exhibited high-grade cord compression or MSCC and the full cohort received spinal decompression surgery followed by SR within a median of 48 days after surgery. Postoperative SR provided durable local control, with a cumulative local progression incidence of 16.4% at 1 year (95% confidence interval: 10.7--22.2).

Thus, for patients presenting with spinal cord compression, separation surgery followed by SR is a safe and effective treatment option. Integrative treatment (i.e., SR and separation surgery) may reduce the extent of surgery and also provide faster and more effective radiotherapy treatment.

### Reirradiation of Spinal Metastases

SR is an indicated treatment for cases requiring reirradiation of spinal levels and may be associated with superior tumor control rates and pain relief relative to conventional radiotherapy. However, care must be taken when a reirradiation volume either contains or is very close to the spinal cord, esophagus or other organs at risk. In the reirradiation setting, SR provides a local control rate of 66-93% and a low rate of toxicity when treatment constraints and quality assurances are respected [@b45-cln_71p101][@b46-cln_71p101][@b47-cln_71p101].

### Complications

A pain flare or acute worsening of pain has been found to occur in 20% of cases after SR. Such a flare may occur within 24 hours of single-dose radiation or a few days after the use of a hypofractionated scheme [@b48-cln_71p101],[@b49-cln_71p101]. The pain is usually transient and can be managed with corticosteroids or non-steroidal anti-inflammatory drugs. Radiation-induced spinal cord injury can be a severe event, but it is not often observed. The best method of preventing myelopathy is avoidance of unnecessary radiation to the spinal cord and adherence to planned dose constraints.

Vertebral fracture (VCF) is a common event after SR. VCF has an incidence of approximately 20% and is associated with higher doses per fraction (≥20 Gy) and with 3 of the 6 original Spinal Instability Neoplastic Score (SINS) [@b50-cln_71p101] components, including baseline VCF, a lytic tumor and spinal deformity [@b51-cln_71p101]. Attention must be paid to identifying high-risk patients who would benefit from prophylactic kyphoplasty.

Other events, such as risk of mucositis and skin dermatitis, have also been associated with SR. Additionally, there are many factors that may influence SR toxicity. Such factors include tumor proximity to and extension in adjacent normal tissues, concurrent systemic therapy and targeted therapy and comorbidities (e.g., acute infection, prior surgery, diabetes, collagen vascular disease, or any genetic predisposition).

Thus, in SR, end-to-end patient assessment, planning and dosimetry are important for ensuring a safe treatment procedure.

### Future Perspectives: Randomized Data and Combination Targeted Therapy

Multiple prospective and retrospective series on SR have been reported. There are increasing expectations for randomized phase III trials, prospective phase II studies and the use of molecularly targeted agents as a new approach to treatment. Data from phase I, II and III trials are summarized in [Table 3](#t3-cln_71p101){ref-type="table"} [@b9-cln_71p101],[@b52-cln_71p101],[@b53-cln_71p101],.

The RTOG is currently enrolling patients for a phase III trial, which is estimated to include 380 patients. The anticipated completion of primary data collection for this trial is July 2015 [@b9-cln_71p101]. The trial compares 2 groups of patients: the first arm consists of patients undergoing SR (16 Gy delivered in a single fraction), while the second arm consists of patients undergoing conventional external beam radiotherapy treatment (800 cGy delivered in a single fraction). The patients will be stratified according to number of spine metastases treated (1 *vs*. 2-3) and radioresistant tumor classification (with radioresistant tumors including soft tissue sarcomas, melanomas, and renal cell carcinomas). The primary outcome is to determine whether SR improves pain control (measured by the 11-point Numerical Rating Pain Scale \[NRPS\]) compared with conventional external beam radiotherapy. The following secondary outcomes are also included: pain response and pain/lesion control at a treated site(s) compared with conventional external beam radiotherapy, as measured by the NRPS; local control; adverse events measured by NCI CTCAE v3.0 criteria; and long-term side effects (24 months) of SR on vertebral bone (e.g., vertebral compression fractures) and spinal cord, as measured by MRI.

MSKCC and collaborators are conducting a phase II RCT with an estimated enrollment of 200 patients and a primary anticipated completion date of October 2015. This trial includes patients over 18 years in age with metastatic lesions in the bone, spine, soft tissue and lymph nodes that have not been previously irradiated. The patients will be randomized into 2 groups: the first arm will receive SR using a single dose of 24 Gy and the second arm will be treated with fractioned SR using 27 Gy delivered in 3 fractions [@b30-cln_71p101]. The primary outcome is a comparison of loco-regional control rates at 24 months. The secondary outcomes are a toxicity comparison at 24 months, determination of failure patterns between the two cohorts at 24 months, and SUV uptake as a measure of tumor response and changes in tumor perfusion evaluated by dynamic contrast-enhanced (DCE)-MRI.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is currently conducting a phase I study that aims to assess the safety of prescribing either SR or stereotactic brain radiosurgery (SRS) in combination with ipilimumab (Bristol-Myers Squibb, New York, NY) to treat patients with newly diagnosed brain or spinal metastases from melanoma. The estimated enrollment is 30 patients, with a primary completion date of December 2016. The primary outcomes are a description of the number and severity of adverse events at 24 months and an assessment of the safety profile of SBRT with concurrent ipilimumab. The secondary outcomes include estimates of local control rates in the brain and spine at 24 months, determination of the systemic control rate and evaluation of progression-free survival [@b59-cln_71p101]. Recently published data have reported that using a combination of ipilimumab plus SRS for melanoma brain metastasis is well tolerated and associated with better loco-regional control and possibly better survival rates. However, there was a 20% rate of grade 3 or 4 toxicity using this treatment modality [@b53-cln_71p101].

A retrospective series evaluated 106 metastatic renal cell carcinoma patients (55 spine and 51 brain metastases) who were treated with simultaneous standard sorafenib or sunitinib (anti-angiogenic therapy) and stereotactic radiosurgery (SRS) or SR. The patients received an average dose of 20 Gy per lesion (range, 19--20 Gy) [@b54-cln_71p101]. The study showed no skin toxicity, neurotoxicity or myelopathy augment the adverse effects of anti-angiogenic therapy. Additionally, no treatment-related deaths or late complications were reported at 15 months. The local control rates for cerebral lesions at 12 and 24 months were 100% and 96.6%, respectively; for spinal lesions, the local control rates at 12 and 24 months were 94.1% and 90.4%, respectively. This series demonstrated that the use of SR / SRS plus anti-angiogenic therapy in this setting is safe and provides excellent local control.

The use of SR for metastatic tumors of the spine is safe and offers high local control rates. There are extensive data regarding pain control and local control; however, these data are mostly derived from retrospective and nonrandomized prospective series. Further studies are needed to determine appropriate SR fractionation schedules and clinical indications. Two RCTs (clinicaltrials.gov numbers NCT00922974 and NCT01223248) are ongoing and may provide the data needed to gain better insight into the factors that constitute optimal therapy. There is increasing interest in and a subsequent need to characterize combination drug therapy with SR to enhance local control and even improve survival in select groups of patients.
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![Spine radiosurgery. Target definition (vertebral body), radiotherapy isodose lines (upper right) and dose distribution (below). The axial and sagittal views illustrate "dose-shaping" promoted by IMRT, with sparing of the spinal cord and esophagus. \[Male, 62 years old, metastatic melanoma of the spine, stable lesion, ECOG 0, treated with SR via 18 Gy delivered in a single fraction. The distance between the GTV (gross target volume) and the medulla is approximately 2 mm\].](cln-71-02-101-g002){#f2-cln_71p101}

![Depth dose curves for photons, cobalt 60, protons and carbon ions.](cln-71-02-101-g003){#f3-cln_71p101}

###### 

Current NOMS decision framework for high-grade epidural spinal cord compression (ESCC) (Adapted from Laufer et al. [@b24-cln_71p101]).

  Neurologic                         Oncologic        Mechanical   Systemic                     Decision
  ---------------------------------- ---------------- ------------ ---------------------------- ----------------------------------------------
  **High-grade ESCC ± myelopathy**   Radiosensitive   Stable                                    CRT
                                                      Unstable                                  Stabilization followed by CRT
                                     Radioresistant   Stable       Able to tolerate surgery     Decompression / stabilization followed by SR
                                     Radioresistant   Stable       Unable to tolerate surgery   CRT
                                     Radioresistant   Unstable     Able to tolerate surgery     Decompression / stabilization followed by SR
                                     Radioresistant   Unstable     Unable to tolerate surgery   Stabilization followed by CRT

CRT: Conventional radiotherapy; SR: Spine radiosurgery.

###### 

Important clinical results following spine radiosurgery (based on recent prospective and retrospective data).

  Author                              Study design                             SR indication                                      N / Dose                                                       IGRT                                                                                                                                     Reported results
  ----------------------------------- ---------------------------------------- -------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ahmed et al. [@b55-cln_71p101]      Prospective case series                  SM: primary and reirradiation                      66 patients(85 lesions)24 Gy (SF and HF)                       BodyFix or thoracic-T double vacuum system[\*](#tfn3-cln_71p101){ref-type="table-fn"}ExacTrac X-ray system with a 6D robotic couch^\#^   mOS (12 months): 52.2%LC (1 year): 91.2%No grade 4 toxicity
  Amdur et al. [@b56-cln_71p101]      Prospective case series                  SM: primary and reirradiation                      21 patients(12 reirradiation)Dose: 15 Gy                       Customizedbody mold / onboard cone-beam CT                                                                                               OS (12 months): 60%43% pain reliefNo grade 3 or 4 toxicity
  Garg et al. [@b57-cln_71p101]       Prospective case series                  SM: primary SR                                     61 patients(63 tumors)16-24Gy (SF)                             BodyFix / stereotactic localizer and target frame                                                                                        LC (18 months): 88%?Supports SR as first-line treatment
  Klish et al. [@b58-cln_71p101]      Prospective case series                  SM: reirradiation                                  58 patientsDose: variable                                      BodyFix / stereotactic localizer and target frame                                                                                        LC (12 months): 89.3%\< 5% of isolated failures of the nonirradiated adjacent vertebral body = focal SR feasible
  Garg et al. [@b45-cln_71p101]       Prospective case series                  SM: reirradiation                                  59 patients(63 tumors)30 Gy (5 fractions)27 Gy (3 fractions)   BodyFix stereotactic body frame system / stereotactic localizer and target frame                                                         OS (12 months): 76%LC (12 months): 100%Freedom from neurological injury: 92%
  Gerszten et al. [@b22-cln_71p101]   Prospective nonrandomized cohort study   SM: primary and reirradiation                      500 patients12.5 - 25 Gy (SF and HF)                           CyberKnife: Aquaplast facemask\$                                                                                                         LC: 90% of primary lesions and 88% of lesions treated for radiographic tumor progressionClinical improvement (previous neurologic deficit): 84%Long-term pain improvement: 86%
  Haley et al. [@b59-cln_71p101]      Prospective case series                  Efficacy and cost effectiveness of CRT versus SR   44 patients(22 CRT and 22 SR)Dose: variable                    CyberKnife system                                                                                                                        Similar pain reliefNo late complications in either groupCRT: more acute toxicities and was more likely to require additional interventions
  Folkert et al. [@b32-cln_71p101]    Retrospective case series                SM: primary and reirradiation (sarcoma)            120 lesions(SF and HF 24 Gy)                                   Noninvasive customized cradle / onboard imaging (orthogonal KV imaging and cone-beam CT)                                                 OS 60%LC (12 months) 87.9%Low toxicity reported
  Zelefsky et al. [@b60-cln_71p101]   Retrospective case series                SM: primary and reirradiation (renal cell)         105 lesions(SF and HF)Dose: 24 Gy                              Customized cradle / digitally reconstructed radiographs from the simulation studies for each field\'s beam\'s eye view                   PFS (36 months - HF): 17%PFS (36 months -SF 24 Gy): 88%SF: improve local control

**Legend:** N: number of patients; IGRT: image-guided radiotherapy; SF: single fraction; HF: hypofractionated; SM: spine metastasis; Hypo: hypofractionated; LC: local control; OS: overall survival; PFS: progression-free survival; SR: spine radiosurgery; CRT: conventional radiotherapy; CT: computed tomography.
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###### 

Spine radiosurgery. Interventions and primary outcome descriptions from clinical trials registered at clinicaltrials.gov.

  Study / Date started                        Status                    Design                         Condition           Intervention                                                           Primary outcomes
  ------------------------------------------- ------------------------- ------------------------------ ------------------- ---------------------------------------------------------------------- ---------------------------------
  NCT01654068 [@b61-cln_71p101] / Jul, 2012   Recruiting                Phase II                       Spinal metastasis   1\) 2-3 SM: 14 Gy SF2) 1 SM: 14 Gy SF                                  Any skeletal-related event
  NCT01223248 [@b52-cln_71p101] / Oct, 2012   Recruiting                Phase III                      Spinal metastasis   SR 24 Gy SF *vs*. SR, 27 Gy (HF)                                       Loco-regional control rates
  NCT01290562 [@b62-cln_71p101] / Jun 2011    Recruiting                Phase II                       Spinal metastasis   20-24 Gy SF; or 20-24 Gy (HF)No prior RT or prior RT or Post-op        Local control: image / symptoms
  NCT00573872 [@b63-cln_71p101] / Dec 2007    Not recruiting (active)   Phase I/II                     Spinal metastasis   Phase 1: 20-25 Gy (HF) / Phase 2: 9-24 Gy (SF)                         TT: Safety
  NCT01849510 [@b64-cln_71p101] / Apr 2013    Recruiting                Phase II(2 arms)               Spinal metastasis   HF: 12×3 Gy+integrated boost 12×4 Gy / CRT 10×3 Gy                     Local control
  NCT02167633 [@b65-cln_71p101] / Jul 2014    Recruiting                Controlled (2 arms)            MSCC                Decompression surgery plus CRT / SR 16 Gy SF                           Ambulatory status
  NCT00853528 [@b66-cln_71p101] / Feb 2009    Not recruiting (active)   Phase I                        Spinal metastasis   Maximum tolerated dose HF SR                                           Dose escalation
  NCT00631670 [@b67-cln_71p101] / Feb 2008    Completed                 Controlled                     Spinal metastasis   15 Gy SF / 25×2.8 Gy                                                   Safety
  NCT01525745 [@b68-cln_71p101] / Jan 2012    Completed                 Phase II                       Spinal metastasis   SR HF / CRT 10 fractions                                               Pain control: NPRS
  NCT01826058 [@b69-cln_71p101] / Apr 2013    Recruiting                Phase II                       MSCC                16 -24 Gy SF / 21-36 HF                                                Neurologic response
  NCT01254903 [@b70-cln_71p101] / Dec 2012    Recruiting                Phase I                        MSCC                18 Gy SF                                                               Safety
  NCT00922974 [@b9-cln_71p101] / Nov 2009     Recruiting                Phase II: completedPhase III   Spinal metastasis   SR 16 Gy SF / CRT 1×800 cGy                                            Pain control
  NCT01752036 [@b71-cln_71p101] / Mar 2013    Recruiting                Phase II                       Spinal metastasis   SR: 30 Gy (HF)                                                         Safety
  NCT01347307 [@b72-cln_71p101] / Sep 2008    Not recruiting(active)    Phase IV                       Spinal metastasis   Benign: 12-16 Gy SF; 21-27 Gy HFMetastases: 14-25 Gy SF; 21-30 Gy HF   Tumor control
  NCT01231061 [@b73-cln_71p101] / Nov 2010    Completed                 Phase II                       Spinal metastasis   Arm 1:SR 24 Gy HF / SR 16 Gy SF                                        Pain control
  NCT01950195 [@b53-cln_71p101] / Jun 2013    Recruiting                Phase I                        Spinal metastasis   SR+ipilimumab                                                          Safety
  NCT01624220 [@b74-cln_71p101] / Jun 2012    Recruiting                Assignment                     Spinal metastasis   SR+4 gold seeds implanted                                              Safety

SR: spine radiosurgery; NPRS: numeric pain rating scale; TT: tomotherapy; QA: quality assurance; SF: single fraction; HF: hypofractionated; CRT: conventional radiotherapy; Post Op.: post operative; MSCC: metastatic spinal cord compression.
